Inatherys SAS recently presented preclinical data for INA-03, an anti-transferrin receptor (TfR1/CD71) antibody-drug conjugate (ADC), being developed for the treatment of triple-negative breast cancer (TNBC). INA-03 was constructed by conjugating an antimitotic payload (MMAE) to a humanized IgG4 anti-human CD71 antibody using a novel valine-citrulline linker.
Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting moiety reported to be useful for the treatment of arthritis, Behçet’s disease, chronic obstructive pulmonary disease, non-small-cell lung cancer, inflammatory disorders, inflammatory bowel disease, psoriasis and rheumatoid arthritis.
Université Laval has identified PBRM derivatives acting as estradiol 17β-dehydrogenase 1 (HSD17B1; 17β-HSD1) inhibitors reported to be useful for the treatment of cancer.
Laekna Pharmaceutical Ningbo Co. Ltd. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) and its mutant (H1047R) inhibitors reported to be useful for the treatment of breast cancer.
Scientists at Dongguk University and Korean Research Institute of Bioscience and Biotechnology have disclosed benzofuran compounds targeting heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1) acting as RAF proto-oncogene serine/threonine-protein kinase (RAF-1; c-Raf) inhibitors reported to be useful for the treatment of cancer.
Prostate cancer (PC), often referred to as a cold tumor, typically presents a poor immune response, making it difficult for immune-based therapies to be effective. Metastatic castration-resistant PC (mCRPC) presents a highly aggressive phenotype often refractory to systemic treatment.
Aprea Therapeutics Inc. has entered into a material transfer agreement with MD Anderson Cancer Center that will support investigation of APR-1051 as a potential treatment for head and neck squamous cell carcinoma (HNSCC).
Shanghai Apeiron Biotechnology Co. Ltd. has divulged kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and Kartagener syndrome (primary ciliary dyskinesia).
Haisco Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an androgen receptor (AR) targeting moiety acting as AR degradation inducers reported to be useful for the treatment of prostate cancer.
Astrazeneca AB has synthesized antibody-drug conjugates comprising an antibody or antigen-binding fragment covalently linked to cytotoxic moieties through enzymatically cleavable linkers reported to be useful for the treatment of cancer.
RSS
